Connectyx Technologies Signs Marketing Agreement with Hereditary

[Guest guest]

Connectyx Technologies Signs Marketing Agreement with Hereditary

Neuropathy Foundation

Company to Promote MedFlash® Personal Health Manager Directly to HNF Membership

http://www.connectyx.com/pressReleases/CTYX%20Press%20Release%20-%20%20HNF%20-%2\

0June%209%202010.pdf

PALM CITY, FL—June 9, 2010 – (PRNEWSWIRE) Connectyx Technologies Holdings Group

Inc.

(OTCPK:CTYX) is pleased to announce that the Company has signed a marketing

agreement with the Hereditary Neuropathy Foundation (HNF), a non-profit

organization that focuses on raising awareness, funding scientific research, and

educating the medical community as well as the general public about

Charcot-Marie Tooth disease (CMT). HNF offers people with CMT, and their

families, medical information and emotional support. The agreement will allow

Connectyx to promote its MedFlash® Personal Health manager directly to

Hereditary Neuropathy Foundation's membership and their families, through HNF's

membership benefit program located on their web site.

Charcot-Marie-Tooth disease (CMT) is a hereditary motor-sensory neuropathy

(HMSN). HMSNs are a group of progressive neurological disorders that affect the

motor and sensory units of the peripheral nervous system. CMT causes weakness

because the nerve signals are impaired (demyelinated) before they reach the

muscle. Over time this

causes atrophy (a loss of muscle strength) in various areas of the body such as

the feet, legs, hands, and diaphragm. CMT is considered to be the most commonly

inherited form of peripheral neuropathy affecting approximately one in 2,500

adults. CMT is diagnosed by clinical features of muscle atrophy, age of onset,

electromyography (EMG), nerve biopsy and through genetic testing.

, Founder & President of the Hereditary Neuropathy Foundation,

understands the importance of having one's medical history with them at all

times. 's father had CMT but she had virtually no symptoms of CMT until

she was mistakenly given a drug that caused her to have a severe onset of CMT

symptoms including gait

imbalance, muscle weakness and severe fatigue. . " HNF is thrilled to become a

strategic partner of Medflash. It is critical that CMT patients carry with them

at all times a list of neurotoxic drugs to avoid potentially debilitating or

even lethal side effects from contraindicated drug treatments.

Furthermore, when dealing with a genetic neurological

disease like CMT, family history is critical to diagnosis and treatment. It can

not only prevent medical catastrophes

but also reduce unneccessary testing to obtain a diagnosis. "

HNF promotes and supports both clinical and primary CMT research. The foundation

is also actively committed to increasing awareness of the disease through all

available media outlets, including print, radio and television as well as

fundraising programs. While HNF members give a face to CMT, the foundation

provides a strong, organizational

voice to those living with CMT all over the world. HNF continues to educate

physicians, along with the entire medical community, about CMT. They are a

critical source of information for the general public about this important,

often misunderstood disease.

" We are excited about the relationship with the Hereditary Neuropathy

Foundation. The MedFlash Personal Health Manager will be a valuable tool for

their members, " stated Ronn Schuman, President and CEO of Connectyx Technologies

Holdings Group, Inc.